Skip to main content

rylaze

Generic: asparaginase erwinia chrysanthemi (recombinant)-rywn·Code: JZP458

rylaze: sourced relationships with 1 company · 1 FDA decision.

rylaze evidence translation

What we can confirm

What it means

Source-backed records connect rylaze to JAZZ; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could rylaze → JAZZ affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Use as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL or LBL in adults and pediatric patients aged one month or older who have developed hypersensitivity to E. coli-derived asparaginaseAcute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in patients with hypersensitivity to E. coli-derived asparaginase

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Jazz Pharmaceuticals plc (JAZZ)
developer · Reported 2026-02-24 · Current development: unknownSource
Use as a component of a multi-agent chemotherapeutic regimen…
Approved
Jazz Pharmaceuticals plc (JAZZ)
Reported 2021-06-30 · Current development: unknownSource
Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. ( 1 )(JAZZ)FDA ↗
BLA761179Type 1 - New Molecular EntityOrphan DrugStandardSubcutaneousInjectable

Frequently asked questions

Which companies have sourced relationships with rylaze?

rylaze has dated SEC/FDA relationship records for Jazz Pharmaceuticals plc.

What is rylaze's latest FDA decision?

The most recent tracked FDA decision for rylaze is Approval for 1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. ( 1 ), dated June 30, 2021.